Humacyte Inc

Humacyte Inc

HUMA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$105.38M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Humacyte IncHumacyte Inc-0.8--253%-2.1
$1.50

Target Price by Analysts

233.3% upsideHumacyte Target Price DetailsTarget Price
$-0.11

Current Fair Value

124.1% downside

Overvalued by 124.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$105.38 Million
Enterprise Value$91.66 Million
Earnings per Share$-0.26
Beta2.44
Outstanding Shares234,182,284

Return

Return on Equity-253.43%ROE
Return on Assets-57.37%
Return on Invested Capital-77.99%

Valuation & Multiples

P/E Ratio-0.81P/E Ratio
PEG35.54PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue43.22
Enterprise Value to EBIT-0.95
Enterprise Value to Net Income-2
Total Debt to Enterprise0.72
Debt to Equity2.12Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 17, 2026
EPS Estimate
$-0.11
Consensus analyst estimate
Revenue Estimate
$2.02 M
Consensus analyst estimate

Next Earnings Call

Expected Date
November 6, 2026
EPS Estimate
$-0.09
Consensus analyst estimate
Revenue Estimate
$1.02 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 50.83%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.27%▼ 37.50%
Total Invested$328,643▼ 99.44%
Investors Holding10▼ 164.00%

About Alpha Healthcare Acquisition Corp.

CEO: Mr. Rajiv Sarman Shukla

Alpha Healthcare Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in New York, New York.

Humacyte Insider Information FAQ

Stockcircle tracks 5 top investors with a current 13F position in Humacyte. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 3 top investors increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 5 open-market insider purchases and 2 open-market insider sales for Humacyte in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.